SCHEMBL17547426

SCHEMBL17547426

O=C1c2c(O)c(=O)c3c(n2CCN1Cc1ccc(F)cc1)COC/C=C\C3

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.38
GRM2 Q14416 1/20 0.38
AKR1B1 P15121 1/20 0.36
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
TP53 P04637 2/20 0.34
CLPP Q16740 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17547432 0.84 AKR1B1 (0.39) KCNH2GRM2AKR1B1RAB9AALDH1A1
SCHEMBL16185333 0.84 AKR1B1 (0.39) KCNH2GRM2AKR1B1RAB9AALDH1A1
SCHEMBL16185214 0.77 GRM2 (0.38) KCNH2GRM2AKR1B1RAB9AALDH1A1
SCHEMBL17547427 0.76 TP53 (0.41) KCNH2GRM2RAB9AALDH1A1POLB
SCHEMBL16185317 0.75 CLPP (0.35) KCNH2GRM2CLPP
SCHEMBL16185316 0.74 CLPP (0.38) KCNH2GRM2AKR1B1CLPP
SCHEMBL17547425 0.73 CLPP (0.38) KCNH2GRM2ALDH1A1CLPPLMNA
SCHEMBL5126325 0.72 KCNH2 (0.47) KCNH2GRM2AKR1B1RAB9AALDH1A1
SCHEMBL4144158 0.70 GRM2 (0.50) KCNH2GRM2AKR1B1RAB9AALDH1A1
SCHEMBL16185325 0.70 GRM2 (0.34) KCNH2GRM2CLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493479-B2 Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-9493479-B2 Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-03 US disclosed
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS PNPO, TYMP, PDXK KCNH2 2585/4885GRM2 4171/4885AKR1B1 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.